183 related articles for article (PubMed ID: 34128829)
1. Targeting androgen receptor signaling: a historical perspective.
Davies AH; Zoubeidi A
Endocr Relat Cancer; 2021 Jul; 28(8):T11-T18. PubMed ID: 34128829
[TBL] [Abstract][Full Text] [Related]
2. Endocrine therapy: where do we stand and where are we going?
Schröder FH
Cancer Surv; 1991; 11():177-94. PubMed ID: 1841751
[TBL] [Abstract][Full Text] [Related]
3. Intermittent androgen deprivation therapy in advanced prostate cancer.
Alva A; Hussain M
Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor: past, present and future.
Schmidt LJ; Tindall DJ
Curr Drug Targets; 2013 Apr; 14(4):401-7. PubMed ID: 23565753
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
Singer EA; Golijanin DJ; Messing EM
Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
[TBL] [Abstract][Full Text] [Related]
7. Hormonal Therapy for Prostate Cancer.
Desai K; McManus JM; Sharifi N
Endocr Rev; 2021 May; 42(3):354-373. PubMed ID: 33480983
[TBL] [Abstract][Full Text] [Related]
8. Interplay between orphan nuclear receptors and androgen receptor-dependent or-independent growth signalings in prostate cancer.
Wang Y; Gao W; Li Y; Chow ST; Xie W; Zhang X; Zhou J; Chan FL
Mol Aspects Med; 2021 Apr; 78():100921. PubMed ID: 33121737
[TBL] [Abstract][Full Text] [Related]
9. Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.
Nishiyama T; Suzuki K; Yamana K; Tonegawa E; Wako K; Takahashi K
Expert Rev Anticancer Ther; 2006 Feb; 6(2):259-68. PubMed ID: 16445378
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
Taplin ME
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
[TBL] [Abstract][Full Text] [Related]
11. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
12. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
Crawford ED; Schellhammer PF; McLeod DG; Moul JW; Higano CS; Shore N; Denis L; Iversen P; Eisenberger MA; Labrie F
J Urol; 2018 Nov; 200(5):956-966. PubMed ID: 29730201
[TBL] [Abstract][Full Text] [Related]
13. Combined androgen blockade: the gold standard for metastatic prostate cancer.
McLeod DG; Crawford ED; DeAntoni EP
Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
[TBL] [Abstract][Full Text] [Related]
14. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
[TBL] [Abstract][Full Text] [Related]
15. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.
Mostaghel EA; Page ST; Lin DW; Fazli L; Coleman IM; True LD; Knudsen B; Hess DL; Nelson CC; Matsumoto AM; Bremner WJ; Gleave ME; Nelson PS
Cancer Res; 2007 May; 67(10):5033-41. PubMed ID: 17510436
[TBL] [Abstract][Full Text] [Related]
16. [Metastatic hormone-sensitive prostate cancer: more than just androgen-deprivation therapy].
Mechahougui H; Achard V; Friedlaender A
Rev Med Suisse; 2020 May; 16(695):1098-1101. PubMed ID: 32462838
[TBL] [Abstract][Full Text] [Related]
17. Recent trends in the management of advanced prostate cancer.
Ritch C; Cookson M
F1000Res; 2018; 7():. PubMed ID: 30345007
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.
Karantanos T; Corn PG; Thompson TC
Oncogene; 2013 Dec; 32(49):5501-11. PubMed ID: 23752182
[TBL] [Abstract][Full Text] [Related]
19. A Review on the Effects of Androgen Deprivation Therapy (ADT) on Bone Health Status in Men with Prostate Cancer.
Mohamad NV; Soelaiman IN; Chin KY
Endocr Metab Immune Disord Drug Targets; 2017 Nov; 17(4):276-284. PubMed ID: 28925899
[TBL] [Abstract][Full Text] [Related]
20. Optimal pharmacotherapeutic management of hormone-sensitive metastatic prostate cancer.
Alva A; Hussain M
Drugs; 2013 Sep; 73(14):1517-24. PubMed ID: 23959841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]